Drugs / Bemotrizinol
Bemotrizinol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04355286 | Nov 2020 | — | dsm-firmenich Switzerland AG | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00530387 | Jul 2008 → Jul 2011 | photoallergic dermatitis | NHS Tayside | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT05254912 Comparator | Mar → Apr 2022 | photoallergic dermatitis | dsm-firmenich Switzerland AG | Completed | No outcome recorded |
| Phase 2 | NCT05254925 Comparator | Feb → Mar 2022 | phototoxic dermatitis | dsm-firmenich Switzerland AG | Completed | No outcome recorded |
| Phase 2 | NCT05260359 Comparator | Feb → Apr 2022 | sunburn | dsm-firmenich Switzerland AG | Completed | No outcome recorded |
| Phase 3 | NCT05277376 Comparator | Mar → Oct 2022 | — | dsm-firmenich Switzerland AG | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bemotrizinol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05277376 ↗ |
| Known as | BEMT | “6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation (SU E 101413 85)” NCT05254912 ↗1“6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation” NCT05260359 ↗ |
| Known as | FAT 70'884 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104956 ↗ |
| Known as | NSC-759870 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104956 ↗ |
| Known as | Tinosorb S | “Tinosorb S” NCT00530387 ↗ |
| Modality | Small molecule | — CHEMBL2104956 ↗ |
| Route | Topical | “subjects will receive a topical application of the study drug” NCT04355286 ↗ |